Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kirk Sanders

Internal Medicine Danbury, NC Medical Doctor

NPI 1699088732 CMS profile 1066170

1020 Hospice Dr, Danbury, NC 27016

Open in the dashboard

General payments

$9,356

581 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kirk Sanders of Danbury, NC is reported in the CMS Open Payments database as having received $9,356 across 581 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,088 59
2024 General $1,145 63
2023 General $1,532 91
2022 General $1,448 93
2021 General $1,690 105
2020 General $1,169 78
2019 General $1,284 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kirk Sanders
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kirk Sanders were reported at $1,088. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kirk Sanders Internal Medicine median Middle half National median
2019 $1,284 $159 $48–$570 $163
2020 $1,169 $119 $33–$402 $114
2021 $1,690 $135 $37–$521 $132
2022 $1,448 $141 $42–$496 $149
2023 $1,532 $149 $45–$519 $160
2024 $1,145 $154 $47–$537 $164
2025 $1,088 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,398 82 payments
  2. Novo Nordisk Inc $1,294 100 payments
  3. Pfizer Inc. $1,188 64 payments
  4. Lilly USA, LLC $990 71 payments
  5. Sanofi-Aventis U.S. LLC $441 25 payments
  6. Paratek Pharmaceuticals, Inc. $402 28 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $385 26 payments
  8. GlaxoSmithKline, LLC. $260 18 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $235 14 payments
  10. Merck Sharp & Dohme Corporation $194 11 payments
  11. Other $2,568 142 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,339 579 payments
  2. Education $17 2 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS $956 48 payments
  2. Ozempic $793 63 payments
  3. RYBELSUS $717 53 payments
  4. NURTEC ODT $524 25 payments
  5. FARXIGA $517 30 payments
  6. BREZTRI $457 26 payments
  7. NUZYRA $402 28 payments
  8. XIFAXAN $399 27 payments
  9. PAXLOVID $389 19 payments
  10. EMGALITY $308 23 payments
  11. Other $7,507 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 158 drugs

Part D claims

10,265

Median for Internal Medicine: 777

Drug cost

$917,736

Median for Internal Medicine: $73,373

Branded share of claims

23.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 121 $139,399
Eliquis Apixaban Brand 160 $121,120
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 53 $56,078
Mounjaro Tirzepatide Brand 39 $42,703
Trulicity Dulaglutide Brand 15 $33,591
Xarelto Rivaroxaban Brand 55 $33,048
Jardiance Empagliflozin Brand 52 $31,406
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $30,867
Myrbetriq Mirabegron Brand 42 $27,806
Janumet Sitagliptin Phos/Metformin Hcl Brand 25 $26,910

The 10 drugs with the highest cost, of 158 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$18,241

Medicare's payments for the services billed

Medicare patients

71

Average age 75

Services billed

464

45 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 35%
COPD 32%
Ischemic heart disease 31%
Chronic kidney disease 31%
Heart failure 27%
Atrial fibrillation 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $108
$108 — —
ELIQUIS
  • PFIZER INC. $83
  • E.R. Squibb & Sons, L.L.C. $20
$103 160 —
MOUNJARO
  • Lilly USA, LLC $99
$99 39 —
Wegovy
  • Novo Nordisk Inc $92
$92 — —
Prolastin-C Liquid
  • Grifols USA, LLC $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

581 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record